Solar Pharmaceutical Industries on Wednesday beat Road estimates for the December quarter with a consolidated web revenue of ₹3,369 crore, up 16% from ₹2,903 crore reported within the year-ago interval. The Mumbai-based drugmaker mentioned its income from operations rose 15.1% year-on-year to ₹15,469 crore.
The corporate noticed regular income development in its branded enterprise in India and rising markets in addition to in international modern gross sales, offsetting the decline in gross sales of Revlimid.
A Bloomberg ballot had pegged the drugmaker’s income to develop to ₹14,792 crore with revenue after tax at ₹3,035 crore for the quarter.
The pharmaceutical firm’s earnings earlier than curiosity, taxes, depreciation, and amortization (Ebitda) for the quarter was ₹4,948.5 crore, up 23.4%, whereas the margin was 31.9%, up from 29.3% a yr in the past.
“Our outcomes this quarter display effectively‑rounded development throughout all companies, prominently led by our Branded companies in India, Rising Markets and International Progressive Medicines. Our modern product providing has expanded additional with the launch of Unloxcyt within the US and the introduction of Ilumya in India,” Kirti Ganorkar, managing director, mentioned in a press release.
Area-wise gross sales
Solar Pharma’s US generic gross sales have been at $477 million, marginally up by 0.6% YoY. Progressive medicines continued to develop, offsetting the decline in generics enterprise, the corporate mentioned. US gross sales accounted for roughly 27.5% of whole consolidated gross sales.
Its international modern drugs gross sales have been at $423 million for Q3FY26, which included a milestone revenue of $55 million. Ex-milestone, international modern drugs gross sales have been up 13.2% and accounted for 21.2% of gross sales.
Solar Pharma‘s modern gross sales outpaced generic gross sales within the US for the primary time within the September quarter, pointing to the corporate’s shift in focus in direction of novel medication.
There’s uncertainty across the potential impact of the most-favoured nation (MFN) drug pricing norms being enforced within the US. Underneath the MFN drug pricing norms, drug producers are required to match the bottom worth supplied for a drug in different developed nations, and is a part of the Trump administration’s push to localise and make healthcare cheaper for Individuals.
Solar Pharma has not introduced any potential affect but.
Its India gross sales grew 16.2% to ₹4,999 crore, outpacing the expansion of the general Indian pharmaceutical market. India gross sales accounted for 32.3% of total gross sales.
Solar’s market share in India elevated from 8.1% to eight.4% as per Pharmarack’s MAT December 2025 report.
Earlier this month, Solar Pharma introduced that it had obtained approval from the central regulator to launch semaglutide for weight administration and plans to launch it as soon as its patent expires in March.
Solar Pharma’s share worth closed at ₹1,595.00 on the NSE on Friday, marginally up at 0.36%.